SLS — SELLAS Life Sciences Group, Inc. - Common Stock
Session close: $14.86. Regular-session share volume: 26,585,490. Change from previous close: -17.21%.
Key developments
SELLAS Life Sciences priced an underwritten public offering of common stock at a per-share price, expecting gross proceeds of roughly one hundred fifty million dollars before underwriting discounts and expenses. The company granted underwriters a thirty-day option to purchase additional shares at the same price, with J.P. Morgan, TD Cowen and Mizuho serving as book-running managers. The offering is expected to close the following day, subject to customary closing conditions. The capital raise is a financing development that dilutes existing holders while funding the late-stage cancer therapy developer.
Company mentioned — Mentions SLS in the article text. SELLAS Life Sciences Prices $150 Million Underwritten Public Offering · Company mentioned — Mentions SLS in the article text. SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering